Key View 

• A lack of current effective treatment is driving research into disease modifying therapies (DMTs) for Parkinson’s disease (PD). 
• We expect Alpha Synuclein (ASN) Inhibitors will be the first form of DMT for PD to receive FDA approval. 
• Drugs which engage neuronal rescue pathways, like GLP-1 agonists, have also shown promise in the

Key View

• Reducing healthcare costs and expanding access to care will remain a priority for the US government, but the November presidential election poses downside risks to policy continuity. 
• As the burden of mental illnesses rises in the US, investments in healthcare personnel and preventive and therapeutic measures will continue to

Key View

• Further dismissals of lawsuits targeting the Inflation Reduction Act (IRA) will continue to pose downside risks to drugmakers in the US.
• Negotiations will set a precedent for drug pricing, as drugmakers present counter offers to Centers for Medicare and Medicaid Services (CMS). 
• Drugmakers and relevant stakeholders implicated in

Key View 

• Data centre hyperscalers are shifting their focus toward powering their infrastructure with nuclear energy.
• In particular, Small Modular Reactors (SMRs) are gaining popularity due to their scalable clean energy output and safety features, which are considered superior to those of larger-scale projects.
• Our Power team highlights

Core View

• We continue to view the presidential election as a toss-up. As the incumbent with a strong economy, President Joe Biden has a structural advantage. However, Donald Trump leads in the national polls and in most of the key swing states (Arizona, Georgia, Michigan, Nevada, North Carolina, Ohio and Pennsylvania).
• We anticipate that the

The Latest: On March 5 2024, the US Food and Drug Administration (FDA) approved Dexcom’s Stelo Glucose Biosensor System, marking the first FDA approval of an over the counter (OTC) continuous glucose monitor (CGM). The device is an integrated CGM that is to be worn on the upper arm and lasts for up to 15 days before it needs to be replaced. It is

Key View

• Recent positive regulatory developments in Europe and the US will enhance J&J’s multiple myeloma drug portfolio. 
• J&J’s multiple myeloma drug, Carvykti, will outperform Bristol-Myers Squibb’s Abecma, its closest competitor, further strengthening J&J’s oncology business.
• The FDA’s growing caution of CAR T-cell therapies will pose

The Latest: On February 23 2024, the US FDA approved Simlandi (adalimumab-ryvk), a biosimilar to AbbVie’s blockbuster drug Humira (adalimumab). The approval marks a significant milestone for Teva and its partner, Alvotech, as Simlandi becomes the first high-concentration, citrate-free biosimilar to Humira with an interchangeability designation in

Concerns surrounding the health of the US commercial real estate (CRE) market and potential economic implications intensified following the poor earnings reported by New York Community Bank on January 31. The situation has since appeared to stabilise, though still elevated interest rates and looming maturity walls will likely see CRE risks

Key View

• Merck’s Q423 and FY2023 financial results highlight the continued importance of Keytruda (pembrolizumab) sales for the company’s revenues.
• Recent regulatory approvals in new indications and earlier lines of treatment for certain cancers will support Keytruda's growth momentum over the short-to-medium term.
• Merck will continue its